Opendata, web and dolomites

EASIVIRAL SIGNED

EASIVIRAL

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EASIVIRAL project word cloud

Explore the words cloud of the EASIVIRAL project. It provides you a very rough idea of what is the project "EASIVIRAL" about.

see    stated    feasibility    time    virus    received    crisis    venture    alone    region    210m    2024    excellence    patient    accuracy    kit    biotechnologies    grow    blood    partners    september    ltd    exists    detection    techniques    structure    viruses    diagnoses    granted    seal    load    easiviral    disrupt    patents    clinical    2015    prescription    rt    ceo    outcomes    laboratories    proven    gt    supply    purify    life    cumulative    market    clinics    significantly    offers    competitiveness    altratech    stops    acceptance    create    portability    viral    hepatitis    poc    format    portfolio    decades    people    accelerated    elimination    robustness    centered    revenues    30    innovative    biomarkers    12    sme    successful    intervention    vl    saving    75    therapy    enhances    made    manufacturing    critical    combination    innovations    detect    refrigerated    ebitda    phc    local    urges    spread    1b    2016    care    labs    simultaneous    exceeded    jobs    commercialise    portable    threshold    battery    share    combo    solution    improvements    diagnostics    disruptive    reagents    trl    hiv    mins    capacity    point    capture    displace    18m    76    operated    pcr   

Project "EASIVIRAL" data sheet

The following table provides information about the project.

Coordinator
ALTRATECH LIMITED 

Organization address
address: 4TH FLOOR 103/104 O CONNELL STREET
city: LIMERICK
postcode: V94 AT85
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.easiviral.com
 Total cost 2˙969˙000 €
 EC max contribution 2˙969˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALTRATECH LIMITED IE (LIMERICK) coordinator 2˙969˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

In September 2016 WHO-Europe stated “Europe is at a critical point with HIV. New diagnoses in the European Region recently increased by 76%”. WHO urges “an accelerated people-centered response” based on taking HIV viral-load (VL) testing out of labs and into local clinics where it is most needed at point-of-care (PoC). No such solution exists today. New disruptive innovations are needed to address this. AltraTech Ltd has developed three proven biotechnologies to capture, purify, and detect the HIV virus from a blood sample, in 40 mins, using proven HIV biomarkers. This enables life-saving clinical intervention, immediate prescription and therapy for the patient, and stops further spread of the virus. The three techniques are innovative. Their combination, in a portable battery-operated kit format, is disruptive. It offers the unique combination of portability, robustness, reduced cost, with simultaneous increase in accuracy, combo-detection of Hepatitis and other viruses, and elimination of refrigerated reagents. It will address the above crisis, the HIV-VL PoC market, and has the potential to disrupt the €1B viral clinical diagnostics market and displace RT-PCR diagnostics that have been used in laboratories for two decades. Following a successful SME-Phase-1 feasibility, the technology received a Seal-of-Excellence in Phase-2(PHC-12-2015) – exceeded funding threshold. TRL improvements have been made in 2016, and a new CEO, management structure, and new venture funding significantly enhances AltraTech capacity to commercialise EASIVIRAL and see it reach market acceptance. The outcomes will enable capture a market leading share of > 30% of the €210M PoC HIV-VL market, reach cumulative EBITDA for this product alone of more than €18M by 2024. AltraTech will create 75 new jobs during this time, grow its portfolio of granted patents on its disruptive EASIVIRAL technology, and increase the revenues, jobs, and competitiveness of its manufacturing supply partners

 Deliverables

List of deliverables.
1000 fabricated silicon sensor chips Demonstrators, pilots, prototypes 2020-02-12 16:28:30
Poster showing lower-limit of quantification Websites, patent fillings, videos etc. 2020-02-12 16:28:31
Data Sheets, App Notes, White Papers, Publicity material Websites, patent fillings, videos etc. 2020-01-30 10:06:41

Take a look to the deliverables list in detail:  detailed list of EASIVIRAL deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EASIVIRAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EASIVIRAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More